A Phase 2b Diabetic Kidney Disease Study

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 609 participants.

Also called NCT04170543

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 609 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04170543
Other papers using this trial's data
  • Inhibition of IL-33 in Diabetic Kidney Disease: A Randomized, Placebo-Controlled Phase 2b Trial Journal of the American Society of Nephrology : JASN, 2026-05-01 DOI, PubMed 41563367, PMC13143461 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Canada, Chile, Japan, Peru, South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04170543. Randomized; quadruple masking; primary purpose treatment. Start 2019-11-18 (actual); primary completion 2023-05-16 (actual). Results posted on 2024-07-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2b Diabetic Kidney Disease Study
Condition
Diabetic Kidney Disease
Intervention (Drug)
MEDI3506
Intervention (Drug)
Placebo
Intervention (Drug)
Dapagliflozin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct04170543
Content hash
f2361da776f9c97060ff37f131eec66ca978eee47f7383fe44f6e35676b8c8ec